Olema Pharmaceuticals, Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| BUTITTA CYNTHIA M | — | Option Exercise | 83,876 | $4.41 | $369,893 | 83,876 | Sep 16, 2020 |
| Harmon Cyrus | Chief Technology Officer | Award / Grant | 143,472 | — | — | 1,040,172 | Jun 15, 2020 |
| Kovacs Shane William Charles | Ch. Operating & Financial Off. | Award / Grant | 358,680 | — | — | 358,680 | Jun 15, 2020 |
| Kushner Peter J. | Chief Scientific Officer | Award / Grant | 143,472 | — | — | 1,072,752 | Jun 15, 2020 |
| Myles David C. | Chief Development Officer | Award / Grant | 143,472 | — | — | 591,821 | Jun 15, 2020 |